Pricing

Biogen Inc. (BGEN)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
14 CAMBRIDGE CTR CAMBRIDGE, MA 02142

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Biogen Inc.'s principal activity is to develop, manufacture and market novel human therapeutic products. The Group currently sells AVONEX (r) for the treatment of relapsing multiple sclerosis (MS) and commencing in 2003, AMEVIVE (r) for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. It also has a significant number of ongoing research programs. The products of the Group are marketed in the United States, Europe, Asia and other foreign countries. Vaccines and diagnostic products accounted for 90% of 2002 revenues and Royalties, 10%.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available